Dr. Gish was first in Pharmacy School at the University of Kansas and then obtained his medical degree from the University of Kansas Medical School in Kansas City, Kansas. He completed a 3-year internal medicine residency at the University of California, San Diego, and a 4-year gastroenterology and hepatology fellowship at the University of California, Los Angeles which included transplant medicine.
Dr. Gish is a fellow of the American Association for the Study of Liver Disease. He has served on the editorial boards of American Journal of Gastroenterology, Hepatology, Journal of Hepatology, Digestive Diseases and Sciences, and Gastroenterology, among many others. He has coauthored a public health policy for liver health in Vietnam focusing on HBV and is also assisting with the development of viral hepatitis health care policies in Armenia and the Philippines. He was a major early contributor to decipherment methods for the detection of hepatitis B and C virus and characterizing its epidemiology and clinical presentation in humans. He was involved in studies that led to the genotypic classification strategies and methods now in use worldwide. He has published more than 700 original articles, review articles, abstracts, and book chapters.
Dr. Gish is currently an Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD. In addition, he is also Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania.
Marion G. Peters, MD
Professor Emeritus, Medicine
Dr. Peters works in the NIH AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group (TSG) where she has been a driving force in the development of US and international studies for new drugs for patients with HBV, with and without HIV. She is an Emeritus Professor of Medicine at the University of California at San Francisco and an Adjunct Professor of Medicine at Northwestern University. She received her Bachelor of Medicine/Bachelor of Surgery degree and her Doctorate of Medicine from Melbourne University Medical School in Melbourne, Australia. She is a hepatologist with a particular interest in viral hepatitis. Her research focuses on viral hepatitis in complicated clinical settings, patients with co-morbid conditions including alcoholism and HIV infection. She has numerous publications on viral hepatitis with and without HIV co-infection in peer-reviewed journals with multiple collaborators.
Tarik Asselah, MD, PhD
Professor, Medicine, Hepatology
Dr. Asselah is a Full Professor of Medicine and Hepatology at Hopital Beaujon, APHP, Clichy, France and at the University Paris Diderot, France, and further is Head of Viral Hepatitis at INSERM (UMR 1149, Centre de Recherche sur l’Inflammation).
Dr. Asselah’s fields of research include chronic liver diseases, translational medicine and treatment of HBV and HCV infections with new direct-acting antivirals, for which he has been involved as a coordinator/principal investigator in several clinical trials. Of note, he has coordinated major international clinical trials on HCV Genotype 4 infection.
Dr. Asselah has published over 250 articles in the field of chronic liver diseases in major journals (NEJM, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, etc…). (H-index = 60) and was selected as a rising star in Gastroenteology in 2009 by the United European Gastroenterology (UEG) in appreciation of his outstanding scientific work. He received awards for his genomic studies on HCV in 2005 from the French Association for the Liver Disease (AFEF), and for his leadership in Hepatology in 2019 from the Czech Hepatology Society. Dr Asselah is an MD and holds a PhD in virology.